Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 152

1.

Ketamine: translating mechanistic discoveries into the next generation of glutamate modulators for mood disorders.

Zarate CA Jr, Machado-Vieira R.

Mol Psychiatry. 2017 Mar;22(3):324-327. doi: 10.1038/mp.2016.249. No abstract available.

PMID:
28070122
2.

Convergent lines of evidence support the role of uric acid levels as a potential biomarker in bipolar disorder.

Machado-Vieira R, Salem H, Frey BN, Barbosa IG, Teixeira AL.

Expert Rev Mol Diagn. 2017 Feb;17(2):107-108. doi: 10.1080/14737159.2017.1270758. No abstract available.

PMID:
27935358
3.

Antisuicidal Response Following Ketamine Infusion Is Associated With Decreased Nighttime Wakefulness in Major Depressive Disorder and Bipolar Disorder.

Vande Voort JL, Ballard ED, Luckenbaugh DA, Bernert RA, Richards EM, Niciu MJ, Park LT, Machado-Vieira R, Duncan WC Jr, Zarate CA Jr.

J Clin Psychiatry. 2016 Dec 6. doi: 10.4088/JCP.15m10440. [Epub ahead of print]

PMID:
27929610
4.

Increased Brain Lactate During Depressive Episodes and Reversal Effects by Lithium Monotherapy in Drug-Naive Bipolar Disorder: A 3-T 1H-MRS Study.

Machado-Vieira R, Zanetti MV, Otaduy MC, De Sousa RT, Soeiro-de-Souza MG, Costa AC, Carvalho AF, Leite CC, Busatto GF, Zarate CA Jr, Gattaz WF.

J Clin Psychopharmacol. 2017 Feb;37(1):40-45. doi: 10.1097/JCP.0000000000000616.

PMID:
27902528
5.

GSK-3: A key regulatory target for ketamine's rapid antidepressant effects mediated by enhanced AMPA to NMDA throughput.

Zarate CA Jr, Machado-Vieira R.

Bipolar Disord. 2016 Dec;18(8):702-705. doi: 10.1111/bdi.12452. No abstract available.

PMID:
27900801
6.

Change in cytokine levels is not associated with rapid antidepressant response to ketamine in treatment-resistant depression.

Park M, Newman LE, Gold PW, Luckenbaugh DA, Yuan P, Machado-Vieira R, Zarate CA Jr.

J Psychiatr Res. 2017 Jan;84:113-118. doi: 10.1016/j.jpsychires.2016.09.025.

PMID:
27718369
7.

Update on bipolar disorder biomarker candidates.

Teixeira AL, Salem H, Frey BN, Barbosa IG, Machado-Vieira R.

Expert Rev Mol Diagn. 2016 Nov;16(11):1209-1220.

PMID:
27737600
8.

Mood Therapeutics: Novel Pharmacological Approaches for Treating Depression.

Henter ID, de Sousa RT, Gold PW, Brunoni AR, Zarate CA Jr, Machado-Vieira R.

Expert Rev Clin Pharmacol. 2017 Feb;10(2):153-166. doi: 10.1080/17512433.2017.1253472.

PMID:
27781556
9.

Intestinal Dysbiosis, Gut Hyperpermeability and Bacterial Translocation: Missing Links Between Depression, Obesity and Type 2 Diabetes.

Slyepchenko A, Maes M, Machado-Vieira R, Anderson G, Solmi M, Sanz Y, Berk M, Köhler CA, Carvalho AF.

Curr Pharm Des. 2016;22(40):6087-6106.

PMID:
27669970
10.

Increased Activity or Energy as a Primary Criterion for the Diagnosis of Bipolar Mania in DSM-5: Findings From the STEP-BD Study.

Machado-Vieira R, Luckenbaugh DA, Ballard ED, Henter ID, Tohen M, Suppes T, Zarate CA Jr.

Am J Psychiatry. 2017 Jan 1;174(1):70-76. doi: 10.1176/appi.ajp.2016.15091132.

11.

Genetic Studies on the Tripartite Glutamate Synapse in the Pathophysiology and Therapeutics of Mood Disorders.

de Sousa RT, Loch AA, Carvalho AF, Brunoni AR, Haddad MR, Henter ID, Zarate CA, Machado-Vieira R.

Neuropsychopharmacology. 2017 Mar;42(4):787-800. doi: 10.1038/npp.2016.149. Review.

PMID:
27510426
12.

Familial aggregation and heritability of the melancholic and atypical subtypes of depression.

Lamers F, Cui L, Hickie IB, Roca C, Machado-Vieira R, Zarate CA Jr, Merikangas KR.

J Affect Disord. 2016 Nov 1;204:241-6. doi: 10.1016/j.jad.2016.06.040.

PMID:
27450632
13.

Acute risk factors for suicide attempts and death: prospective findings from the STEP-BD study.

Ballard ED, Vande Voort JL, Luckenbaugh DA, Machado-Vieira R, Tohen M, Zarate CA.

Bipolar Disord. 2016 Jun;18(4):363-72. doi: 10.1111/bdi.12397.

PMID:
27233466
14.

Bias in emerging biomarkers for bipolar disorder.

Carvalho AF, Köhler CA, Fernandes BS, Quevedo J, Miskowiak KW, Brunoni AR, Machado-Vieira R, Maes M, Vieta E, Berk M.

Psychol Med. 2016 Aug;46(11):2287-97. doi: 10.1017/S0033291716000957.

PMID:
27193198
15.

Antidepressant Efficacy of Adjunctive Aerobic Activity and Associated Biomarkers in Major Depression: A 4-Week, Randomized, Single-Blind, Controlled Clinical Trial.

Siqueira CC, Valiengo LL, Carvalho AF, Santos-Silva PR, Missio G, de Sousa RT, Di Natale G, Gattaz WF, Moreno RA, Machado-Vieira R.

PLoS One. 2016 May 6;11(5):e0154195. doi: 10.1371/journal.pone.0154195.

16.

Corrigendum: Long-term NMDAR antagonism correlates reduced astrocytic glutamate uptake with anxiety-like phenotype.

Zimmer ER, Torrez VR, Kalinine E, Augustin MC, Zenki KC, Almeida RF, Hansel G, Muller AP, Souza DO, Machado-Vieira R, Portela LV.

Front Cell Neurosci. 2016 Apr 11;10:93. doi: 10.3389/fncel.2016.00093.

17.

The role of adipokines in the rapid antidepressant effects of ketamine.

Machado-Vieira R, Gold PW, Luckenbaugh DA, Ballard ED, Richards EM, Henter ID, De Sousa RT, Niciu MJ, Yuan P, Zarate CA Jr.

Mol Psychiatry. 2017 Jan;22(1):127-133. doi: 10.1038/mp.2016.36.

18.

Evidence for increased motor cortical facilitation and decreased inhibition in atypical depression.

Veronezi BP, Moffa AH, Carvalho AF, Galhardoni R, Simis M, Benseñor IM, Lotufo PA, Machado-Vieira R, Daskalakis ZJ, Brunoni AR.

Acta Psychiatr Scand. 2016 Aug;134(2):172-82. doi: 10.1111/acps.12565.

PMID:
27028276
19.

Therapeutic Modulation of Glutamate Receptors in Major Depressive Disorder.

Jaso BA, Niciu MJ, Iadarola ND, Lally N, Richards EM, Park M, Ballard ED, Nugent AC, Machado-Vieira R, Zarate CA.

Curr Neuropharmacol. 2017;15(1):57-70. Review.

PMID:
26997505
20.

Cognitive impairment in late-life bipolar disorder is not associated with Alzheimer's disease pathological signature in the cerebrospinal fluid.

Forlenza OV, Aprahamian I, Radanovic M, Talib LL, Camargo MZ, Stella F, Machado-Vieira R, Gattaz WF.

Bipolar Disord. 2016 Feb;18(1):63-70. doi: 10.1111/bdi.12360.

PMID:
26876913
Items per page

Supplemental Content

Loading ...
Support Center